Preview: India's Sun Pharma rises as analysts expect specialty portfolio to power Q2 growth
BUZZ-PREVIEW-India's Sun Pharma rises as analysts expect specialty portfolio to power Q2 growth ** Shares of Sun Pharmaceutical Industries SUN.NS rise 2.9% to 1,812.30 rupees ahead of Q2 results
** Analysts forecast high single-digit to low double-digit revenue growth, led by the India business and specialty portfolio
** Nuvama expects India formulations and specialty drugs to drive another quarter of healthy growth, offsetting weakness in the US business
** Kotak Institutional Equities sees domestic sales remaining robust, while continuing erosion in gRevlimid revenue weighs on US growth
** Motilal Oswal expects specialty therapies including Leqselvi and Winlevi to support revenue momentum despite a softer generic backdrop
** Avg rating of 31 analysts at "buy"; median PT 2,180 rupees - LSEG-compiled data
** YTD, SUN up 5.3% vs pharma index's .NIPHARM nearly 20% climb
(Reporting by Kashish Tandon in Bengaluru)
Recent news on Sun Pharmaceutical Industries
See all newsROI-US blue wave reshapes Asia's winners and losers: Manishi Raychaudhuri
Brief: Sun Pharma Clarifies Regarding News Report Relating To Company's Assam Facility
Street View: India's Sun Pharma Organon buy, psoriasis drug are risk factors
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses